Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer...

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30% Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANG...
Streetwise Reports | October 8, 2019 |

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...
Streetwise Reports | December 5, 2019 |

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-20...
Streetwise Reports | December 12, 2019 |

Could DehydraTECH CBD be Worth $3 Billion a Year to Lexaria?

PCG Digital -- Hypertension, or high blood pressure as it's commonly known, affects over three million Americans every year and is a primary or contributing cause of death for 25% of them. On a global scale, hypertension kills roughly 7.6 milli on people per year . L...
Featured Submission | March 9, 2021 |

Buzz on the Bullboards: Who’s filling the void in the tech selloff?

Last week was full of tough questions for investors navigating the waters of a sea of global economic uncertainty and confusion. Investors remain in a holding pattern as we witnessed some of the most popular companies among our communities (many in the tech sector) st...
Jonathon Brown | February 1, 2024 |

Protagonist's Shares Nearly Double After Reporting Q1 Earnings and Positive Phase 2 Trial Results

Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer. After U.S...
Streetwise Reports | May 11, 2020 |

Buzz on the Bullboards: A Snapshot of the Latest & Hottest Small Cap Trends

(Image via Gatekeeper Systems Inc.) It has been another interesting week for markets on Bay Street and Wall Street, from a hot streak to a slide, back up, and down again. Every sector has seen its share of gainers and decliners, with the Stockhouse Bullboards tracki...
Stockhouse Editorial | November 18, 2020 |

Five Feet High And Rising

As a general rule, the most successful man in life is the man who has the best information How high's the water, mama? Five feet high and risin' How high's the water, papa? Five feet high and risin' Well, the rails are washed out north of town We ...
Richard (Rick) Mills | September 6, 2019 |

A Petroleum Co. That’s Poised & Positioned to Help Fill the Global Energy Void

The Russian invasion of Ukraine has shone a bright light on the need for the west – particularly Europe – to find alternative sources of energy and to break its dependence on Russian oil and natural gas. That’s where companies like ShaMaran Petroleum C...
Dave Jackson | May 13, 2022 |

Ticker Trax: Optioning Colombia gold & copper

**This article was delivered to Ticker Trax subscribers Tuesday February 16. We sat a spell in Vancouver, Canada, with Thom Calandra , investor and writer. Thom is the journalist who started CBS MarketWatch and MarketWatch.com – now part of the Dow Jones-News Corp. fami...
Dr. Allen Alper of Metals News | October 28, 2012 |
1 2